ribociclib
novartis
['mbc', 'maintain study', 'ribociclib']
maintain study demonstrates a significant pfs benefit for pts with hr+/her2- mbc who switch et and receive ribociclib after progression on cdk 4/6i. suggestions that only patients with esr wild type bc derive benefit from the switch to ribociclib plus alternative et. #asco2022 
Professor of Translational Oncology and Consultant Medical Oncologist